{
    "links": "https://www.ycombinator.com/companies/granza-bio",
    "name": "Granza Bio",
    "headline": "Advancing Therapeutic Delivery",
    "batch": "W24",
    "description": "Granza Bio is a biotechnology company developing a novel delivery \"shell\" platform to direct therapeutic cargo to specific tissues. Their proprietary delivery vehicles are designed using non-immunogenic proteins equipped with a targeting receptor, achieving targeted tropism to organs of interest. These vehicles offer higher stability than conventional lipid nanoparticles (LNPs) and can encompass a variety of cargo, including proteins, DNA, and RNA.  \r\n\nFor their lead candidate, Granza Bio is leveraging the discovery of the immune system's powerful suite of weapons, \"attack particles\". Utilizing their advanced delivery platform, they aim to target these \"attack particles\" against a range of diseases such as cancer, autoimmune disorders, and infections.   \r\n\nInterested to know more? Get in touch info@granzabio.com!",
    "activity_status": "Active",
    "website": "https://www.granzabio.com/",
    "founded_date": 2024.0,
    "team_size": 5.0,
    "location": "San Francisco",
    "group_partner": null,
    "group_partner_yc": null,
    "company_linkedin": null,
    "company_twitter": null,
    "tags": "industry:synthetic-biology; industry:biotech; industry:healthcare; industry:therapeutics; industry:oncology; location:san-francisco-bay-area",
    "founders": [
        {
            "name": "Ashwin Nandakumar, Founder",
            "description": "Ashwin completed his PhD (DPhil) in Oncology at the University of Oxford. After completing his PhD, he began working as a Cancer Research UK post-doctoral researcher at Oxford University and also at the Institute of Cancer Research (ICR), London. He also brings experience setting up oncology clinical trials and working in oncology start-ups.",
            "linkedin": "https://linkedin.com/in/ashwin-nandakumar-menon"
        },
        {
            "name": "Ashwin Jainarayanan, Founder",
            "description": "Granza Bio, DPhil (PhD) in Interdisciplinary Bioscience - University of Oxford",
            "linkedin": "https://linkedin.com/in/jainarayananak"
        }
    ],
    "status": true,
    "generated_description": "**Granza Bio: Pioneering Precision in Therapeutic Delivery**\n\nFounded in 2024 and part of the Y Combinator Batch W24, Granza Bio operates out of San Francisco and is on a mission to advance therapeutic delivery. The company has ingeniously crafted a novel delivery \"shell\" platform that directs therapeutic cargo to specific tissues using non-immunogenic proteins and targeting receptors. This approach allows them to achieve higher stability compared to conventional lipid nanoparticles while being versatile enough to carry various cargo, including proteins, DNA, and RNA.\n\nAt the heart of Granza Bio's innovation is their lead candidate, which draws from the immune system's impressive arsenal: \"attack particles.\" These autonomous entities, discovered in the lab of co-founder Prof. Dustin at the University of Oxford, are designed to target a range of diseases, notably cancer, autoimmune disorders, and infections. \n\nWhat sets their \u201cprecision shell\u201d technology apart is its ability to recreate these attack particles synthetically, allowing them to operate independently from immune cells. The platform promises to deliver a diverse array of cargo types\u2014ranging from RNA to genetic modifiers\u2014while overcoming the immunological triggers that conventional delivery methods often face.\n\nWith just a small team of five passionate individuals, Granza Bio is poised to revolutionize how we approach therapeutic delivery in healthcare. Their focus on synthetic biology and biotechnology puts them at the forefront of the evolving healthcare landscape.\n\nFor more insights or partnerships, feel free to reach out to them at [info@granzabio.com](mailto:info@granzabio.com) or visit their website [Granza Bio](https://www.granzabio.com/).",
    "logo": "https://bookface-images.s3.us-west-2.amazonaws.com/logos/8dc67611777eb58ef3a44a268c9a31830976bc8b.png?X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=ASIAQC4NIECAEHIR6H6F%2F20250221%2Fus-west-2%2Fs3%2Faws4_request&X-Amz-Date=20250221T191404Z&X-Amz-Expires=3600&X-Amz-Security-Token=IQoJb3JpZ2luX2VjELP%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEaCXVzLXdlc3QtMiJIMEYCIQDt736ZW5EfzagAz1eKRSs%2FW4TfHu28RBSFaRNkZ9h47gIhANt6WXtwkgL07bQKDKYDGFxYKx7WOO9JX0BqaYrXnKNbKu4DCNz%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEQABoMMDA2MjAxODExMDcyIgx8TqkMwTM2PLcRmr4qwgPGGtQBXv7gs7%2BXGteI1gQk%2FjkbIHwQ5hCKXJKVmVAPw3MeVLhZyp8Nf5%2FYigbwE%2BrFR7aZWKjrs7HxAE0JWit5dlINZLjZK%2BS%2FwMaCqoj%2BFDN0gw9iiAPu4Xn5c3b%2BuZe%2F5%2Flfk0EuxZAXVsZtShxXZy%2FERPQ0v%2FRZxSz5qUoaXpL1zj6VWdWVzoI7%2FPlB3bgJ2PpiF7DN%2BJeDsJPx%2FoKTo5ehP9pOeGbMNxoeegVJsCJ3zvzO3o4fcZYIf6c5iIJwM1Ot3Gg7Z3v9oLZjSRU%2FaRLL5j4n3II7DaroOCEVfPlWzTyZM7SNFZZAFSKM8vLKj1VdTr9s3How41zluf%2FOIp7sGNhG%2FjuYJoG%2FmkLFIlYP4wbGrLO69AWnenZyfi1UhAiV6N%2BlAqGnqvpOJh4vq8uNh2eRnXR%2BMVXdq9oVYkm7XFgprL5PDC4ULLyBWqA6kca4z7F4H56nkT%2FsDtT8ek2VOIRIv1Zgcz%2BeeVG7F7AHS4bdbR6eZ3ChY1iQhfPBErh4OiFQM7IqiUKw%2B1CTpvL68xcVN5gjiaDH0Jotw%2BUcW9dMSg9py8xH8qgyiWG5w3dDj9xaoA2G3NMYq6JOGKMwwIrjvQY6pAHDH54nhADhmb7YSEGxHkL3pqs%2B6aYOExStWbzLKzRb3lb2DAgGG8uU9COt8%2FqUEOtOcszTKp7yuCJwMVkfI7PDZ74h9uiRkRxjtH7%2BLlE1xrfd%2FrIq%2B%2BZr9hSFqZ9MUQ4yNHesyx2FYDbsIfCW9ntlrpmZUHCcrzpQDfufsAFcpe%2FudVT3tUqiF8WCN1Vd%2Bx%2FQ9d3i1HvBcJWV9AYAwM0W22VM%2BA%3D%3D&X-Amz-SignedHeaders=host&X-Amz-Signature=b544421ad060d19cbb82711b5f555767bd39c180390c48a57a3f3a0ecf39a2c8",
    "social_links": [
        "https://www.linkedin.com/company/101140973/",
        "https://twitter.com/GranzaBio"
    ],
    "logo_path": "data/logos\\Granza_Bio_logo.png"
}